Cargando…
Cancer immunotherapy strategies that target the cGAS-STING pathway
Activation of the cGAS-STING pathway by cytoplasmic DNA induces the production of Type-1 interferons. Recent advances in research suggest that the cGAS-STING pathway is involved in different parts of the cancer-immunity cycle (CIC) to promote or suppress antitumor immune responses. Combination thera...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639746/ https://www.ncbi.nlm.nih.gov/pubmed/36353640 http://dx.doi.org/10.3389/fimmu.2022.996663 |
_version_ | 1784825705323823104 |
---|---|
author | Tian, Zhuoying Zeng, Yue Peng, Yurong Liu, Junqi Wu, Fang |
author_facet | Tian, Zhuoying Zeng, Yue Peng, Yurong Liu, Junqi Wu, Fang |
author_sort | Tian, Zhuoying |
collection | PubMed |
description | Activation of the cGAS-STING pathway by cytoplasmic DNA induces the production of Type-1 interferons. Recent advances in research suggest that the cGAS-STING pathway is involved in different parts of the cancer-immunity cycle (CIC) to promote or suppress antitumor immune responses. Combination therapy of STING agonists has made certain progress in preclinical as well as clinical trials, but the selection of combination therapy regimens remains a challenge. In this review, we summarize the role of the cGAS-STING in all aspects of CIC, and focus on the combination immunotherapy strategies of STING agonists and current unsolved challenges. |
format | Online Article Text |
id | pubmed-9639746 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96397462022-11-08 Cancer immunotherapy strategies that target the cGAS-STING pathway Tian, Zhuoying Zeng, Yue Peng, Yurong Liu, Junqi Wu, Fang Front Immunol Immunology Activation of the cGAS-STING pathway by cytoplasmic DNA induces the production of Type-1 interferons. Recent advances in research suggest that the cGAS-STING pathway is involved in different parts of the cancer-immunity cycle (CIC) to promote or suppress antitumor immune responses. Combination therapy of STING agonists has made certain progress in preclinical as well as clinical trials, but the selection of combination therapy regimens remains a challenge. In this review, we summarize the role of the cGAS-STING in all aspects of CIC, and focus on the combination immunotherapy strategies of STING agonists and current unsolved challenges. Frontiers Media S.A. 2022-10-24 /pmc/articles/PMC9639746/ /pubmed/36353640 http://dx.doi.org/10.3389/fimmu.2022.996663 Text en Copyright © 2022 Tian, Zeng, Peng, Liu and Wu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Tian, Zhuoying Zeng, Yue Peng, Yurong Liu, Junqi Wu, Fang Cancer immunotherapy strategies that target the cGAS-STING pathway |
title | Cancer immunotherapy strategies that target the cGAS-STING pathway |
title_full | Cancer immunotherapy strategies that target the cGAS-STING pathway |
title_fullStr | Cancer immunotherapy strategies that target the cGAS-STING pathway |
title_full_unstemmed | Cancer immunotherapy strategies that target the cGAS-STING pathway |
title_short | Cancer immunotherapy strategies that target the cGAS-STING pathway |
title_sort | cancer immunotherapy strategies that target the cgas-sting pathway |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639746/ https://www.ncbi.nlm.nih.gov/pubmed/36353640 http://dx.doi.org/10.3389/fimmu.2022.996663 |
work_keys_str_mv | AT tianzhuoying cancerimmunotherapystrategiesthattargetthecgasstingpathway AT zengyue cancerimmunotherapystrategiesthattargetthecgasstingpathway AT pengyurong cancerimmunotherapystrategiesthattargetthecgasstingpathway AT liujunqi cancerimmunotherapystrategiesthattargetthecgasstingpathway AT wufang cancerimmunotherapystrategiesthattargetthecgasstingpathway |